Close Menu

HPV

The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.

The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

The company offers a blood test that detects human papillomavirus-related cancer by measuring tumor tissue-modified viral DNA using droplet digital PCR.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.

The firm's platform, dubbed HNKlear, uses methylation-specific PCR to detect microRNA biomarkers in a patient's blood sample following frontline cancer treatment.

The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.

Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.

The researchers found that changes in histone modification at HPV integration events were correlated with upregulation of nearby genes and endogenous retroviruses.

The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.